Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 15/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 11/20 | 0.55 |
| ▸ | PSMB2 | P49721 | 10/20 | 0.55 |
| ▸ | LONP1 | P36776 | 9/20 | 0.55 |
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.55 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.55 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.55 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.55 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.55 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.55 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.55 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.55 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.55 |
| ▸ | PSMB6 | P28072 | 9/20 | 0.55 |
| ▸ | PSMB10 | P40306 | 9/20 | 0.55 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.55 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.55 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093552 | 1.00 | PSMB5 (0.61) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL13130798 | 1.00 | PSMB5 (0.61) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL464479 | 0.92 | ERBB2 (0.62) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL20093557 | 0.92 | ERBB2 (0.62) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL13130797 | 0.92 | ERBB2 (0.62) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL14754702 | 0.92 | ERBB2 (0.62) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL6859224 | 0.89 | PSMB5 (0.69) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL21558228 | 0.83 | PSMB5 (0.56) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL20093580 | 0.83 | PSMB5 (0.56) | PSMB5ERBB2PSMB1PSMB2LONP1 | |
| SCHEMBL13130831 | 0.83 | PSMB5 (0.56) | PSMB5ERBB2PSMB1PSMB2LONP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | GLUCKSMANN ALEXANDRA (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012044832-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | FETZER OLIVER S (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2011146638-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | CERULEAN PHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011090940-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2010114770-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885ERBB2 1529/4885PSMB1 6/4885 |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | PSMB5 1016/4885ERBB2 1043/4885PSMB1 1551/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885ERBB2 1529/4885PSMB1 6/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB5 1149/4885ERBB2 1487/4885PSMB1 1846/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | PSMB5 650/4885ERBB2 4032/4885PSMB1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.